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Abstract
Urothelial carcinoma of the bladder (UCC) is a common dis-
ease that arises by at least two different molecular pathways.
The biology of UCC is incompletely understood, making the
management of this disease difficult. Recent evidence impli-
cates a regulatory role for microRNA in cancer. We hypothe-
sized that altered microRNA expression contributes to UCC
carcinogenesis. To test this hypothesis, we examined the ex-
pression of 322 microRNAs and their processing machinery
in 78 normal and malignant urothelial samples using real-
time rtPCR. Genes targeted by differentially expressed micro-
RNA were investigated using real-time quantification and
microRNA knockdown. We also examined the role of aberrant
DNA hypermethylation in microRNA downregulation. We
found that altered microRNA expression is common in UCC
and occurs early in tumorogenesis. In normal urothelium
from patients with UCC, 11% of microRNAs had altered ex-
pression when compared with disease-free controls. This
was associated with upregulation of Dicer, Drosha, and Expor-
tin 5. In UCC, microRNA alterations occur in a tumor pheno-
type–specific manner and can predict disease progression.
High-grade UCC were characterized by microRNA upregula-
tion, including microRNA-21 that suppresses p53 function.
In low-grade UCC, there was downregulation of many micro-
RNA molecules. In particular, loss of microRNAs-99a/100
leads to upregulation of FGFR3 before its mutation. Promoter
hypermethylation is partly responsible for microRNA downre-
gulation. In conclusion, distinct microRNA alterations charac-
terize UCC and target genes in a pathway-specific manner.
These data reveal new insights into the disease biology and
have implications regarding tumor diagnosis, prognosis and
therapy. [Cancer Res 2009;69(21):8472–81]
Introduction
Bladder cancer is the fifth commonest malignancy in the United
States with an incidence of 67,160 new cases and 13,750 deaths in
2007 (1). The majority of tumors are urothelial cell carcinoma
(UCC). Clinical and molecular evidence suggests there are at least
two distinct varieties of this tumor. Most UCC belong to a low-
grade pathway characterized by FGFR3 mutation, chromosome 9
loss, and an indolent clinical phenotype. Around one-third of
UCC are high grade in differentiation and arise as lesions initially
confined to the bladder mucosa (nonmuscle invasive, NMI). Pro-
gression to muscle invasion occurs in around 50% of high-grade
lesions and is associated with an ominous prognosis despite radi-
cal treatment (2, 3). Although numerous genetic and epigenetic al-
terations are observed in high-grade UCC, loss of p53 function
seems most critical (4, 5).
MicroRNAs (miR) are short noncoding RNA molecules that post-
transcriptionally modulate protein expression. They are tran-
scribed as hairpin pri-miRs and processed into pre-miRs by
Drosha, an RNase III endonuclease complexed with DGCR8. Pre-
MiRs are exported into the cytoplasm by Exportin 5 before cleav-
age by Dicer into mature miRs. MiRs are directed to mRNAs with a
complementary seed sequence to their first 1 to 8 nucleotides (6).
Alterations in mRNA expression seem important for carcinogene-
sis (7, 8). Their profile may be used to identify key tumorogenic
pathways (9) or clinical outcome (10, 11).
To date, few data detail miR in UCC (9, 12, 13). We hypothe-
sized that altered miR expression occurs in UCC and contributes
to carcinogenesis. To test this hypothesis, we investigated the ex-
pression of numerous miRs and their processing molecules in ur-
othelial tissues. Our studies reveal that UCC are characterized by
widespread alterations in miR expression. Changes in expression
occur early in the tumorogenic pathway, in a phenotype-specific
manner, and are associated with altered expression of their pro-
cessing machinery. Of particular note, low-grade tumors are char-
acterized by miR-mediated FGFR3 upregulation before its
mutation.
Materials and Methods
Patients, samples, and cell lines.We studied 72 urothelial samples and
six cell lines (Table 1). Tumors were classified using the 2004 WHO/ISUP
criteria, and selected from three cancer groups: (a) low-grade NMI, (b)
high-grade NMI, and (c) invasive UCC. Twenty normal urothelial samples
were obtained from 10 patients with UCC [NU(UCC) taken distant to any
tumor] and 10 disease-free controls [NU(Controls)]. Tissues were immedi-
ately frozen in liquid nitrogen and histologic confirmation was obtained
before use. Patients were treated according to tumor stage and grade fol-
lowing endoscopic resection (14). Adjuvant intravesical chemotherapy was
used for low-grade and maintenance intravesical Bacillus Calmette-Guerin
(BCG) for high-grade NMI tumors. Patients underwent surveillance strati-
fied by their disease. Radical cystectomy with pelvic lymphadenectomy was
used for invasive or BCG-refractory high-grade NMI tumors (4, 14). We an-
alyzed UCC cell lines representing the three tumor groups (RT4, RT112, and
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EJ/T24, respectively, purchased from American Type Culture Collection)
grown in Dulbecco's medium with 10% FCS, and three normal human ur-
othelial (NHU) cell lines maintained in keratinocyte serum–free medium
containing bovine pituitary extract, epidermal growth factor (Invitrogen),
and cholera toxin. Nonimmortalized NHU cells were derived from histolog-
ically confirmed normal urothelium obtained from patients without a his-
tory of UCC, using standard methods (15). DNA Methyltransferase
inhibition experiments were performed in quadruplet by adding 2 μmol/L
5-azacytidine to the media for 5 to 7 d before harvesting.
MiR expression profiling. For both normal and malignant samples, ten
10 μmol/L sections were microdissected to obtain >90% pure cell popula-
tions. Enriched small and total RNA were extracted using the mirVana kit
(Ambion) according to manufacturer's protocol. RNA concentrations were
measured using a 2100 Bioanalyzer (Agilent, Cheshire). The expression of
354 mature miRs and 3 small nucleolar RNA molecules was determined
using real-time PCR with preprinted microfluidic cards (Human miR
v1.0, Applied Biosystems; ref. 16). Initially, reverse transcription using stem
loop primers was performed with 50 ng RNA, MultiScribe Reverse Tran-
scriptase (Applied Biosystems), RNase inhibitor, 100 nm deoxynucleotide
triphosphates (dNTP) and nuclease-free water. To generate 357 miR and
reference rtPCR products, 8 multiplex pools were used per sample [each
pool containing ingredients and primers for 48 mature miRs: total volume
10 μL (Human Multiplex RT Pool 1-8 v1.0, Applied Biosystems)]. The multi-
plexed RT assays were cooled to 16°C for 30 min, heated to 42°C for 30 min,
and 86°C for 5 min before diluting 62.5-fold in nuclease-free water. From
each diluted assay, 50 μL were mixed equally with 2× Taqman Universal
PCR MasterMix and loaded separately into the eight reservoirs of a micro-
fluidic card (Human miR v1.0, Applied Biosystems). Following careful cen-
trifugation (2 min at 331 grams) and preparation (well sealing and reservoir
removal), the loaded card was analyzed on an ABI 7900HT real-time PCR
system using the recommended PCR conditions. Each microfluidic card
contained MGB-labeled probes specific to 354 mature miRs, 11 duplicate
assays, 2 empty wells, and 17 replicates of 3 endogenous small nucleolar
RNA molecules for relative quantification (RNU6B, RNU44, and RNU48).
MiR concentrations were calculated from the cycle number that each reac-
tion crossed an arbitrarily threshold (Ct = 0.2). The amplification plots were
checked manually (SDS 2.2.1, Applied Biosystems) to confirm the Ct value
corresponded with the midpoint of logarithmic amplification. To test the
reproducibility of this real-time quantification, we analyzed each cell line
and 10 tissue samples in duplicate.
Identification of genes targeted by aberrantly expressed miR. We
identified potential protein targets of miRs using TargetScan7 (version
4.2; refs. 17, 18). Target genes were ranked according to context score
and the average was used for those with multiple targeting miRs. mRNA
transcripts of target and miR-processing genes were measured in those
samples with sufficient material [n = 71 (93%)]. cDNA synthesis from
100 ng whole RNA was performed using random primers, RT buffer, dNTP
(100 mmol/L), RNase inhibitor, and MultiScribe Reverse Transcriptase
(cDNA Reverse Transcription kit, Applied Biosystems). Real-time quantified
PCR using 2 μL of synthesized cDNA, gene-specific primers with FAM-
TAMRA–labeled probes (Supplementary Table S1), water, and 2× Taqman
Universal PCR MasterMix (Applied Biosystems) in a total volume of 10 μL
was performed on the ABI 7900HT system according to manufacturers
guidelines. Relative mRNA quantification was measured with respect to
the mean of glyceraldehyde-3-phosphate dehydrogenase and β-actin (and
PCNA as a proliferation reference gene).
miR knockdown in NHU cells. MiRs-99a/100 targeting of FGFR3 was
investigated using protein expression following miR knockdown and a Lu-
ciferase reporter assay. All experiments were replicated between three and
six times using nonimmortalized NHU cell lines at 70% confluence reverse
transfected with anti–miR molecules specific to miR-99a, miR-100, and a
negative control (scrambled sequence). To determine target protein expres-
sion, NHU cells were transfected with 50 nmol/L anti-miR or control se-
quences using siPORT NeoFX transfection reagent (Ambion). The
mixture was dispensed into a six-well dish, seeded at 2 × 105 cells
per well, and incubated for 48 h. Transfection was determined by
real-time-rtPCR (Applied Biosystems) and FGFR3 expression measured
by Western Blotting using anti-FGFR3 primary antibody (1:1,000; Cell
Signaling Technologies, Inc.). Cells were lysed in radioimmunoprecipita-
tion assay buffer (20 mmol/L Tris·HCl, 135 mmol/L NaCl, 10% glycerol,
1% Igepal, 0.1% SDS, 0.5% deoxycholic acid, 2 mmol/L EDTA) containing
protease and phosphatase inhibitors (Complete EDTA-free protease in-
hibitor cocktail and PhosSTOP phosphatase inhibitor cocktail; Roche),
and protein content was quantified using the DC-protein assay reagent
(Bio-Rad). Protein lysates (50 μg) were loaded onto 8% gels, fractionated,
and electroblotted onto nitrocellulose membranes. After blocking with
5% nonfat milk powder and 0.1% Tween, the membranes were incubated
overnight with anti-FGFR3 primary antibody (1:1,000; Cell Signaling Tech-
nologies, Inc.) at 4°C, washed, and incubated at room temperature for
1 h with goat anti-rabbit peroxidase-labeled secondary antibody
(1:1,000; Cell Signaling Technologies, Inc.). β-Actin expression was also
measured as a loading control (Sigma, 1:2,000). Immune complexes were
quantified using ImageJ for band densitometry. To validate direct target-
ing of FGFR3, NHU cells were cotransfected with either anti–miR-99a,
anti–miR-100, or negative control, and the pSSG_3 untranslated region
(UTR) plasmid containing the luc2P Luciferase reporter and either the
partial 3′UTR for FGFR3 (from 27–1,762 bp downstream of the gene) or
a control (scrambled sequence; SwitchGear Genomics). Cotransfection
was performed in opaque 96-well plates using 40% to 80% confluent cells
and FuGene transfection reagent (Roche) and Opti-MEM serum–free media.
After incubation for 48 h, luciferase activity was determined following the
addition of Promega Steady-Glo Luciferase Assay Reagent (Promega) in a
luminometer. Negative controls using scrambled anti-miR sequences or a
scrambled 3′ UTR sequence were included.
GenerationofFGFR3mutant andwild-typepaired cell lines.Telomerase-
immortalized NHU cells were used to investigate miR expression fol-
lowing FGFR3 mutation (19). Site-directed mutagenesis on FGFR3 IIIb
cDNA created the S249C mutation. The presence of this mutation was
verified by sequencing. Wild-type and mutant FGFR3 were cloned into
a retroviral expression vector (pFB; Stratagene) containing a hygromy-
cin resistance cassette (20). The expression vectors were transfected
into Phoenix A cells using siPORT XP-1 (Ambion). Telomerase-
immortalized NHU were incubated for 8 h with retroviral supernatant
containing 8 μg/mL polybrene and selected with hygromycin 48 h after
transduction. FGF1 cell stimulation was also performed using 20 ng/mL
recombinant human FGF1 and 10 μg/mL heparin (R&D Systems
Europe Ltd.) after 3 h of incubation in depleted medium (KGM2 with-
out added growth factors).
Statistical methods. Relative miR concentrations were calculated with
respect to the median of three reference RNA molecules (ΔCt = Ct miR −
Ct median control). The median was chosen after analysis revealed variation in
concentrations between samples (data not shown). Expression fold changes
were computed using −ΔΔCt calculations (21). Median data centering was
performed before analysis with Significance of Analysis of Microarray soft-
ware (22) and BRB-ArrayTools8 (version 3.7) developed by Dr. Richard
Simon and BRB-ArrayTools Development Team. Class-specific miR signa-
tures were established using Prediction of Microarray software (23). MiR
expression and tumor outcome were investigated using the log-rank test
and plotted by the Kaplan-Meier method within SPSS (version 14.0, SPSS,
Inc.). Tumor progression was defined as the presence of pathologic, radio-
logical, or clinical evidence of an increase in tumor stage and measured
from the time of surgery to the time of proven event. Changes in miR ex-
pression and statistical significance were illustrated using Volcano plots.
Significant expression difference was defined as both a P value of < 0.05
and a false discovery rate of <0.05. Hierarchical clustering was performed
after removal of those miRs with a low detection frequencies in all groups
7 http://www.targetscan.org 8 http://linus.nci.nih.gov/BRB-ArrayTools.html
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(<20%: defined as “noise”) using Cluster 3.0 and visualized in Tree view
(Eisen Lab9). Correlation between variables was assessed using Pearson's
correlation coefficient within SPSS.
Results
MiR expression in normal urothelium. Following assay opti-
mization (Supplementary Results), we compared the expression of
322miRs in normal urothelium from patients with UCC and disease-
free controls. Thirty-six miRs were differentially expressed between
the two groups (P < 0.05 and FDR 0.0; Supplementary Table S2) and
were always upregulated in the NU(UCC). There was clustering of
differential expression according to RNA family, e.g., let-7a/b/c/d/
e/g, miRs-382/487b, miRs-17/93, miRs-181b/d, miRs-34a/c, and
chromosomal location, e.g., 9q22.32 (let-7a/d), 14q32.31 (miRs-
376a/487b/382/412), and 19q13.41 (miRs-520a/b/c/d/e/518a/519e).
Unsupervised hierarchical clustering revealed two branches
corresponding to the two groups (Supplementary Fig. S1). Three
miRs were detected only in NU(UCC) [miR-569 (detected in 50%
of samples), miR-633 (40%), miR-507(30%)] and two by only the
NU(controls) [miR-412 (50%), miR551a (30%); data not shown].
Differential miR expression in malignant urothelium. We
compared malignant miR expression with that from disease-free
normal urothelium (Fig. 1). The annotated raw data can be
downloaded from our website.10 Twelve miRs were expressed
only in the malignant tissues and five to seven of these could
identify cancer with a sensitivity of 90% to 100% and a speci-
ficity of 100% to 80% (Table 2A), suggesting roles as diagnostic
biomarkers. Quantitative analyses revealed that 16 miRs were
differentially expressed in the malignant and normal urothelia
Table 1. Details of patients and tissue samples analyzed in this study
UCC Normal urothelium
Low-grade NMI High-grade NMI Invasive Non-UCC UCC patients
Total 22 12 18 10 10
Gender
Male 14 12 14 10 8
Female 8 0 4 0 2
Age
Mean 75 71.9 71.4 67 66.4
Range 56–83 55–81 46–90 54–81 46–90
Source of urothelium*
TURP 4
RP 6
TURBT 3
RC 7
Grade
1 11 0 0 1†
2 11 0 1 4†
3 0 12 17 5†
Stage
pTa 22 3 0 2†
pTis 0 2 0
pT1 0 7 0
pT2-4 0 0 18 8†
Smoker‡
Current 5 1 3
Ex 13 10 12
Never 4 1 3
Recurrence
Yes 14 8 5
No 8 4 13
Progression
Yes 4 3 11
No 18 9 7
Follow up (mo)
Mean 43.4 57.0 23.5
Range 4–93 15–93 2–84
*RC, radical cystectomy; RP, radical prostatectomy; TURP/BT, transurethral resection of prostate/bladder tumor.
†Details of associated tumour.
‡Ex-smoking status defined as stopping >1 y before tumor.
10 http://www.shef.ac.uk/medicine/research/sections/oncology/medicine-urology/
data.html9 http://rana.lbl.gov/eisen/
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(P < 0.05 and FDR<0.05; Table 2B). Thirteen of these were up-
regulated in cancer and seven of these were also aberrantly ex-
pressed in the normal urothelium from UCC cases, suggesting
early alteration in the disease pathway. Hierarchical clustering
revealed miR expression stratified tissues mostly according to
phenotype.
Genes targeted by aberrantly expressed miR. With Target-
Scan, we identified potential target genes for the 16 differentially
Figure 1. MiR expression in normal and malignant urothelium. Centroid linkage hierarchical clustering was performed after selecting miRs with >90% expression
frequency and mean centering data using city block similarity in Cluster 3.0. First dendrogram row, subsequent progression (black box, progression; white box, no
progression (also in brackets after sample ID (0, no; 1, yes)]. Boxes outline miRs with similar expression profiles.
MicroRNA Profile of Bladder Cancer
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expressed miRs and selected the top one-third, as this fraction
is most associated with altered protein expression (18). Of 1,095
predicted genes, 276 were targeted by more than one miR, in-
cluding PLAG1 by 8 miRs, and E2F7 and DMTF1 by 5. Target
ranking by context score revealed many carcinogenic genes
with high binding affinity (Supplementary Fig. S2). We selected
nine genes, from those with highest binding affinity and poten-
tially carcinogenic roles, and measured their expression in our
urothelial samples. For six of nine genes, there was differential
expression between normal and malignant urothelial (Supple-
mentary Fig. S2C, P < 0.02 t test). For five of these genes, this
differential expression was inverse to that of their targeting
miR, suggesting they play a regulatory role in expression (17).
From UCC gene expression array data (24), we identified 143
putative target genes. For 76 (54%), an inverse relationship be-
tween miR and mRNA expression was present, and in 23 (11%),
this difference reached significance (P < 0.05, t test, Supplemen-
tary Fig. S3).
Expression of miR with respect to tumor phenotype. Com-
parisons of the three tumor groups with disease-free normal
urothelium revealed global and specific differential miR expression
(Figs. 2 and 3). In general, there was a downregulation of miR in
the low-grade samples (18 of 25 differentially expressed miRs) and
an upregulation in high-grade and invasive tumors (28 of 30 and 20
of 20 miRs, respectively; χ2 P < 0.0001). Few aberrantly expressed
miRs were common to the low-grade and high-grade/invasive
cohorts [4 of 59 (6%)], whereas many were shared between the
high-grade and invasive tumors [12 of 38 (32%), χ2 P = 0.003].
The magnitude of differential miR expression varied among tumor
groups [average fold change, 4.32 (low grade), 28.24 (high-grade
NMI), and 50.18 (invasive); ANOVA P = 0.006]. When the three
groups were compared with each other, the low-grade tumors were
distinct from the high-grade NMI (n = 9 miRs differentially ex-
pressed) and invasive cohorts (n = 45 miRs differentially ex-
pressed), whereas no significant differences in expression were
present between the latter two (Fig. 3A).
We defined a specific signature for each tumor group by select-
ing those miRs that were differentially expressed when compared
with both normal urothelium and one or more of the other two
tumor groups (Fig. 3B). As many miRs were shared between the
Table 2. Differences in miR expression between normal and malignant urothelium
A. Absolute expression of a few miRs allows the distinction of malignant and normal urothelium
B. Sixteen MiRs have significant differential expression (P < 0.05 and FDR<0.05) in normal and malignant urothelium when compared*
miR Chr Family Normal Urothelium ΔCt UCC ΔCt Fold change FDR q % P
Present Mean St Dev Present Mean St Dev
miR-649 22 miR-649 90% 18.59 4.11 90% 12.03 2.93 94.00 0.0 0.0019
miR-135b 1 miR-135 100% 7.45 1.53 98% 3.18 2.42 19.41 0.0 0.0037
miR-133b 6 miR-133 100% 0.59 1.93 98% 5.41 3.05 0.04 0.0 0.0041
miR-520b 19 miR-93† 20% 15.00 4.94 77% 11.64 3.94 10.28 0.0 0.0056
miR-204 9 miR-204 100% 4.42 1.85 92% 9.20 3.40 0.04 0.0 0.0063
miR-601 9 miR-601 90% 14.57 3.51 94% 9.92 2.79 24.98 0.0 0.0091
miR-646 20 70% 14.58 3.39 94% 10.04 2.89 23.24 0.0 0.0160
miR-639 19 miR-639 80% 13.29 2.63 90% 8.82 3.16 22.18 0.0 0.0225
miR-380-5p 14 70% 4.41 4.69 75% 10.50 4.34 0.01 2.6 0.0285
miR-21 17 miR-21 100% 2.45 1.56 100% −0.97 2.80 10.71 0.0 0.0296
miR-644 20 miR-644 70% 17.57 3.63 92% 12.66 4.05 30.18 0.0 0.0305
miR-93 7 miR-93† 100% 2.38 2.05 100% −0.45 1.90 7.15 0.0 0.0308
miR-15a 13 miR-15 100% 5.98 1.80 96% 2.89 2.39 8.50 0.0 0.0354
miR-520d 19 miR-93† 30% 21.04 1.02 75% 11.47 4.58 758.94 0.0 0.0394
miR-549 15 miR-549 0% 56% 14.43 3.49 0.00 4.3 0.0427
miR-449b 5 miR-34 100% 12.17 2.24 90% 9.11 2.69 8.36 0.0 0.0439
Abbreviations: FN, false negative; FP, false positive; Sens, sensitivity; Spec, specificity.
*The ΔCt mean and SD values are shown, together with fold change expression associated with carcinogenesis (calculated using the 2-ΔΔCt method).
†miR-93.hd/291-3p/294/295/302/372/373/520.
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high-grade NMI and invasive tumor groups, we merged these to
create a single defining signature. We also identified four miRs that
were altered in UCC regardless of tumor phenotype.
Phenotype-specific miR targets.We were interested by the dif-
ference in miR expression between the low-grade and high-grade
tumors. MiR upregulation was a feature of the high-grade pathway,
and miRs-21/373 were among those with most prominence. Recent
data reveal that miR-21 negatively regulates the p53 tumor sup-
pressor pathway, leading to a loss of cellular control (25). MiR-
373 is known to regulate prometastatic pathways (26), possibly
through LATS2 suppression (of note, LATS2 was downregulated
in our tumors; Supplementary Fig. S2; ref. 8).
Low-grade tumors were characterized by downregulation of
many miRs. Of the 16 miRs with significant downregulation, 7 are
predicted to target FGFR3 (miRs-99a/100/214/145/30a/125b/507)
and 1 is the only highly conserved miR to target H-Ras (miR-218).
We focused upon miRs-99a/100 as they target a highly conserved
8mer region within the FGFR3 UTR and their expression was in-
versely correlated with FGFR3 mRNA (r = −0.48 and −0.52, respec-
tively; P < 0.0004; Fig. 4A). To investigate whether FGFR3 is a target
of miRs-99a/100, we manipulated their expression in NHU cells.
These cells represent normal urothelium, have a 200-fold higher
miR99a/100 expression than RT4 cells and a low FGFR3 expression
(data not shown). Following transfection with anti-miRs, a 70% to
80% reduction in miR expression (data not shown) resulted in an
average 3-fold (miR-99a) and 6-fold (miR-100) upregulation of
FGFR3 protein (Fig. 4). Direct targeting of the 3′ UTR region of
the FGFR3 gene was confirmed by a Luciferase reporter assay
(Fig. 4). Transfection of NHU cells with anti-miRs to 99a/100 and
a plasmid containing Luciferase and a partial FGFR3 3′UTR re-
sulted in a 2-fold (miR-99a) and 3.4-fold (miR-100) increase in Lu-
ciferase expression, when compared with cells transfected with a
scrambled UTR sequence. To investigate the reverse relationship,
we produced matching NHU-TERT cell lines with and without
the S249C FGFR3 mutation. In each cell line regardless of FGF ex-
posure, confluence or passage number the expression of both miRs
was unchanged by the presence of the mutation (Fig. 4D), suggest-
ing the epigenetic event is upstream of the gene mutation.
MiR expression and tumor progression. If miRs-99a/100 and
21/373 characterize low-grade and high-grade UCC, one would
Figure 2. MiR expression in low- and high-grade
bladder cancer. A, changes in expression (log scale)
and statistical significance (SAM P values plotted
as −log 10) of low-grade NMI tumors when compared
with normal urothelium from non-UCC cases reveals
both upregulation and downregulation of numerous
miRs. B, for high-grade NMI and invasive tumors,
there is a general upregulation in miR expression.
Although changes in some miRs are shared between
the two tumor phenotypes (e.g., miR-133b/204), others
seem specific (miR-21 or miRs-100/99a). Expression
is relative to the median of three RNA molecules
and linear median centered.
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expect their expression to be associated with tumor behavior. For
each miR, there was a significant change in tumor progression
rate according to their expression, in a manner similar to their
associated genetic traits (log-rank P < 0.05; Fig. 3C). MiRs-99a/
100 downregulation was associated with a better outcome (anal-
ogous to FGFR3 mutation), whereas miRs-21/373 upregulation
was associated with a worse outcome (as with p53 mutation),
when compared with contrasting tumors. Multivariate analysis
revealed that miR-99a/100 expression was associated with pro-
gression when analyzed together with tumor stage, grade, and
miR-21 expression (Cox MVA P = 0.03 and P = 0.006, respectively).
Epigenetic regulation of miR. The role of aberrant promoter
hypermethylation for miR downregulation in low-grade UCC was
analyzed using DNA methyltransferase inhibition. Following 5-
azactytidine treatment, eight miRs (Fig. 4E) had >2-fold increase
in expression, including six in the low-grade cell line (RT4). The
lower rates of miR re-expression in the high-grade tumor lines
(RT112 and EJ/T24) suggest that regulation by hypermethylation
of these miRs is relatively low-grade specific. Both RT112 and
EJ/T24 have higher rates of DNA hypermethylation than RT4
at known tumor suppressor gene promoters (27). For compari-
son, we analyzed four hypermethylated miRs reported in UCC
(miRs-127/124a/373/517c; refs. 28, 29). For these, re-expression
was usually shared between two or more cell lines rather than
just isolated to RT4. MiRs-99a/100 are located at 21q21.1 and
11q24.1, respectively, together with two other miRs and one pro-
tein coding genes. Neither region contains a canonical CpG
island. To investigate long-range epigenetic silencing of miRs-
99a/100, we looked at the expression of neighboring genes fol-
lowing 5-azactytidine treatment (Supplementary Fig. S4). There
was an increase in expression of mir-125b (located in duplicate
genes, at each locus) but not of either protein coding gene nor
the other miR in RT4.
Processing molecules and miR expression. We analyzed
the expression of molecules known to be important for miR
processing. The expression of each varied significantly between tis-
sue type (ANOVA P < 0.05; Supplementary Fig. S5) but not between
tumor phenotype. For Dicer, Drosha (RNASEN), and Exportin 5,
Figure 3. MiR expression and tumor phenotype.
A, differentially expressed miRs specific to
each phenotype. B, signature panels of miR for
each tissue. C, progression analysis in all 52 UCC
revealed that dichotomous aberrant expression of
miRs-21/100/99a was associated with progression to
more advanced UCC (Kaplan-Meier method and
tested using log-rank analysis).
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there was an upregulation in the normal urothelium from UCC
cases that was reversed once malignancy appeared. The largest
changes were for Dicer and Drosha (7.4- and 6.1-fold upregulation,
P = 0.00006 and 0.00001, respectively), whose expression was close-
ly correlated (Pearson's correlation = 0.79, P = 7 × 10−19). For RAN
and DGCR8 the opposite was seen, with an initial downregulation
followed by upregulation in the tumors. Concentrations of these
two mRNA were almost identical in each tissue (Pearson's correla-
tion = 0.48, P = 3 × 10−6). When expression of these molecules was
compared with that of the 322 miRs, several associations were
seen. Dicer is targeted by several miRs and expression of miR-
130b (r = −0.28, P = 0.02) and let-7g (r = −0.25, P = 0.05) were in-
versely correlated with Dicer expression.
Discussion
Here, we have shown that altered miR expression occurs com-
monly in UCC, in a phenotype-specific manner and targets key
pathways considered “hallmarks” of the disease. Our first finding
was that protumorogenic miR alterations occur before the histo-
logic onset of malignancy, supporting observations of promoter hy-
permethylation and genetic instability (27, 30). Almost half of our
tumor-associated miRs were upregulated in the normal urothelium
from patients with the disease, and this was associated with in-
creased Dicer, Drosha, and Exportin 5 expression. Dicer over-
expression in premalignant lesions of the prostate and lung, and
reduced Dicer and Drosha expression in ovarian cancer are re-
ported (31–33), supporting our observation. Expression of the
miR machinery was not associated with specific miRs, suggesting
a global miR upregulation rather than the selection of tumor-
specific species.
When analyzing all UCC cases together, we found the aberrant
expression of 16 miRs, including some generic to carcinogenesis
[e.g., miR-21 (ref. 25), mir-133b (ref. 34)]. Numerous interesting
observations were apparent. For example, reduced miR-204 ex-
pression was frequent. MiR-204 is located on chromosome
Figure 4. Analyses of miR 99a/100 in
UCC. A, expression of miRs 100/99a and
FGFR3 are inversely correlated (DCt
values shown). B, we found that a 70% to
80% miR-99a/100 knockdown induced
by anti-miRs in NHU cells transcribed with
Luciferase and the 3′UTR of FGFR3 was
associated with increased Luciferase
expression when compared with NHU cells
transfected with a scrambled UTR
sequence. C, upregulation of FGFR3
protein expression was found in NHU cells
transfected with anti-miRs to 99a/100
when compared with negative controls
(scrambled anti-miR sequence; Western
blot images [FGFR3 is top band (splice
variant seen below)] and photometric
relative quantification standardized for
β-actin and measured using ImageJ).
D, the presence of the activating S249C
FGFR3 mutation does not alter miR-99a/
100 expression (relative miR and
mRNA quantification). E, reversal of DNA
hypermethylation leads to re-expression of
5 downregulated miRs in the low-grade
cell line (RT4). Relatively few events were
seen in the cell lines representative of
high-grade and invasive bladder cancer
(RT112 and EJ/T24). Four miRs (mir-127/
124a/373/517c) reported to be silenced
by DNA hypermethylation are also shown
(28, 29).
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9q21.11 within an intron of TRPM3, a gene downregulated in UCC
(35, 36). MiR-204 potentially targets FRS2 an important member
of the FGFR3 pathway (37). Observed changes in miR expression
occurred in isolation or were clustered. Isolated differences arose
from solitary located miRs such as miRs-649/135b or miR-601.
The latter is located within intron 1 of DENND1A, a gene upre-
gulated in UCC (38). Isolated differences also arose when a single
member of a miR cluster was differentially expressed, including
downregulation of miR-133b (adjacent to mir-206) or upregula-
tion of miR-449b (located with miR-449a) and miR-93 (clustered
with miRs-25/106b within the MCM7 gene). Clustered alterations
included downregulation of miRs-133a/1 (located in duplicated
clusters on Chr18q11.1 and Chr20q13.33), miRs-99a/125b, and
miRs-143/145. Familial clustering was also present with three
members of the miR-93 family (miR-93/520b/520d), miR-133a,
and 133b, and three of the miR-34 family (miR-449b/34c/34a)
having aberrant expression. Bioinformatic predictions identified
around 1,000 genes as putative targets of these miRs. Of these
genes, 20% were targeted by more than one miR. We confirmed
consistent expression changes for some of these targets including
new observations suggesting a carcinogenic role for LATS2,
YOD1, and RAB22a in UCC. We identified miR as a potential
mechanism for SOX4 upregulation in UCC (39).
Although the comparison of UCC with normal urothelium re-
vealed interesting data, it did not detail events within the disease
well. To obtain a detailed picture, it was necessary to analyze miR
expression between tumor phenotypes. High-grade tumors were
characterized by miR upregulation and for most, altered expression
occurred before the onset of muscle invasion. Low-grade UCCs
were characterized by miR downregulation and this affected many
molecules targeting FGFR3 or H-Ras. Confirmation of FGFR3 miR
targeting was obtained by the inverse correlation between miR and
mRNA expression, and functional miR knockdown experiments. As
aberrant expression of miRs-99a/100 was almost ubiquitous in low-
grade UCC, occurs more frequently than FGFR3 mutation, and the
presence of the commonest FGFR3 mutation (S249C) did not alter
miR expression, we concluded the miR alteration leads to FGFR3
upregulation before the acquisition of gene mutation. This is an in-
triguing finding and suggests that epigenetic upregulation of FGFR3
facilitates the acquisition of mutation by either increasing cell turn-
over, reducing regulation to make cells more susceptible to carcino-
gens, or providing a selection advantage for mutant cells. To
investigate potential causes of reduced miR expression in low-grade
UCC, we examined DNA methylation. For six miRs, there was sig-
nificant upregulation in RT4 following DNA methyltransferase inhi-
bition, including miR-1 for which aberrant hypermethylation has
recently been reported in hepatocellular carcinoma (40). Our find-
ings with respect to miR-s99a/100 were less clear. There are no ca-
nonical CpG islands close to either gene, but two of the four genes
clustered around miR-99a or miR-100 loci had increased expression
following 5-azacytidine. This finding has been reported by others
(40, 41) and suggests long-range epigenetic regulation (42). How-
ever, the expression of neighboring protein-coding genes did not
alter with DNA Methyltransferase inhibition.
In summary, we have found new mechanisms related to biol-
ogy and progression of UCC. These epigenetic events precede his-
tologic changes of malignancy or disease-progression and occur
in a phenotype-specific manner. These data have implications re-
garding out understanding of UCC tumor biology, and suggest
miR as a novel diagnostic or prognostic biomarker, and therapeu-
tic target.
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